September 2012

Business Without Borders highlights ScarX Therapeutics’ Chinese co-development partnership

September 27, 2012
Susanne Staer
Industry Partners

ScarX Therapeutics, a spin-off company created by MaRS Innovation and The Hospital for Sick Children (SickKids), was profiled by Business Without Borders on September 25, 2012.

Sean Fine‘s article examines the strategic funding partnership MI pursued with NovoTek Therapeutics Inc. (NovoTek) in China to develop the anti-scarring cream, which was discovered by researchers at SickKids.

A multibillion-dollar market may await ScarX, a Toronto biomedical start-up, but first it had to figure out how to finance the development of its unique cream that reduces scarring after surgery.

Its answer to the shortage of Canadian venture capital in life sciences turned out to be a partnership with a drug company in China.

VP Joel Liederman’s Financial Post article on mitigating innovation risk

September 23, 2012
Susanne Staer
Media Coverage

Joel Liederman, vice-president (physical sciences) — Joel Liederman, MI’s vice-president of business development and physical sciences

MaRS Innovation’s Vice-President of Business Development and Physical Sciences Joel Liederman, has published an article in the Financial Post about strategies to mitigate risk within the innovation space.

The article, titled “Innovation Success Means Mitigating Risk,” is featured in the newspaper’s Productive Conversations section.

BioCentury features Encycle Therapeutics and MaRS Innovation in macrocycle chemistry article

September 23, 2012
Susanne Staer
Encycle Therapeutics

Encycle Therapeutics, a MaRS Innovation spin-off company, was included in BioCentury‘s companies to watch within the macrocycle chemistry space.

The reference came in Chris Cain‘s article, “Maturing macrocycle chemistry drives explosion of biotech newcos, biopharma deals.”

CML HealthCare Inc. and MaRS Innovation Enter into Strategic Partnership

September 23, 2012
Susanne Staer
Industry Partners

MISSISSAUGA, Ontario, September 18, 2012 – CML HealthCare Inc. (TSX: CLC) (the “Company” or “CML”) and MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in medical diagnostics.

This story was covered in the Globe and Mail, Canadian Business, 680 News, Reuters, Sympatico.ca, the Huffington Post Canada, Technology Trasnfer Tactics, and the Winnipeg Free Press, among others. It was distributed via Yahoo! Finance, Healthcare Global.com, marketwire and Digital Journal.

Monthly Archives: September 2012

Business Without Borders highlights ScarX Therapeutics’ Chinese co-development partnership

VP Joel Liederman’s Financial Post article on mitigating innovation risk

BioCentury features Encycle Therapeutics and MaRS Innovation in macrocycle chemistry article

CML HealthCare Inc. and MaRS Innovation Enter into Strategic Partnership

Quick Links

Contact Us